[Cardiac magnetic resonance and uremic cardiomyopathy]

Area of Science:

• Nephrology
• Cardiology
• Medical Imaging

Background:

• Cardiovascular disease (CV) is the primary cause of death in chronic kidney disease (CKD) patients.
• CV risk escalates with CKD severity, evident even in early stages.
• Traditional risk factors don't fully explain the high CV event rates in end-stage renal disease (ESRD).

Purpose of the Study:

• To explore the role of cardiac magnetic resonance (CMR) in understanding cardiovascular changes in CKD.
• To investigate non-atherosclerotic mechanisms contributing to CV risk in CKD.
• To characterize uremic cardiomyopathy using advanced CMR techniques.

Main Methods:

• Utilizing cardiac magnetic resonance (CMR) for non-invasive assessment.
• Evaluating cardiac structure and function.
• Assessing arterial function, myocardial tissue characteristics (T1 mapping, inversion recovery), and metabolic function (spectroscopy).

Main Results:

• CMR provides comprehensive insights into adverse CV changes in CKD.
• Identified non-atherosclerotic processes like left ventricular hypertrophy and fibrosis as key contributors to CV risk.
• Uremic cardiomyopathy is better understood through detailed CMR analysis.

Conclusions:

• CMR is crucial for understanding the complex cardiovascular pathology in CKD patients.
• Non-atherosclerotic mechanisms, particularly uremic cardiomyopathy, significantly drive CV morbidity and mortality in CKD.
• Advanced CMR techniques offer a detailed, non-invasive approach to assess cardiovascular health in CKD.